Skip to Main Content

Paper Details

Biomarker Enhanced Risk Prediction for Adverse Outcomes in Critically Ill Patients Receiving RRT.
Clin J Am Soc Nephrol
33
2015
AKI, Acute renal failure, Critically Ill, IL-6, -8, -10, and -18, IL-8, PARTICIPANTS, Patients, bilirubin, critically, critically ill, death receptor-5, macrophage migration inhibitory factor, patients, plasma IL-8, tumor necrosis factor receptor I and II
Author NameAffiliation
Francis PikeThe Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pennyslvania The CRISMA (Clinical Research, University of Pittsburgh Graduate School of Public Health
Raghavan MuruganThe Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pennyslvania The CRISMA (Clinical Research
Christopher KeenerThe Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pennyslvania The CRISMA (Clinical Research, University of Pittsburgh Graduate School of Public Health
Paul M PalevskyThe Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Veterans Affairs Pittsburgh Healthcare System
Anitha VijayanWashington University
Mark UnruhThe CRISMA (Clinical Research, University of Pittsburgh School of Medicine, University of New Mexico
Kevin W FinkelUniversity of Texas Medical School at Houston
Xiaoyan WenThe Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pennyslvania The CRISMA (Clinical Research
John A KellumThe Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pennyslvania The CRISMA (Clinical Research
  • 1 - 9

Datasets

Release 1.2